AnthonyHunterMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Assistant Professor, Emory University School of Medicine, Winship Cancer Institute

Dr. Hunter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2017 - 2020
Emory University School of MedicineResidency, Internal Medicine, 2014 - 2017
Medical College of WisconsinClass of 2014

PubMed

5 citations
Molecular genetics of MDS/MPN overlap syndromes.
Anthony M. Hunter, Eric Padron
Best Practice & Research. Clinical Haematology. 2020-07-05
44 citations
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.
Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun, Najla Al Ali, Onyee Chan
Blood Advances. 2021-02-23
7 citations
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class
Blood Cancer Journal. 2021-03-06

Abstracts/Posters

Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Anthony Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study ...
Anthony M. Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia
Anthony Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
Anthony M. Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019